Cytori Therapeutics Inc. (CYTX) Shares Surge On BARDA Contract Option Execution

Shares of Cytori Therapeutics Inc. (CYTX) are up almost 8% to $1.77 in pre-market trading Tuesday after the company announced that the Biomedical Advanced Research and Development Authority [BARDA], a division of the U.S. Department of Health and Human Services, has executed a contract option to fund the continued investigation and development of Cytori Cell Therapy for use in thermal burn injuries.

Cytori said that the current extension is valued at $12.1 million. Upon IDE approval by the FDA, BARDA anticipates funding to cover costs associated with execution of the clinical trial, currently estimated at $8.3 million, bringing the combined value to up to $20.4 million.

Dr. Marc Hedrick, President and Chief Executive Officer of Cytori said in a statement that his company is “honored to be the first technology in the area of thermal burn to have a contract option executed by BARDA.”

Shares of Cytori Therapeutics traded as high as $1.70 Monday, before ending the day at $1.64. In the past 52 weeks, CYTX has traded between a low of $1.46 and a high of $3.39, which is more than 132% above that low price. Over the past eight months however, the stock has lost 36.19% of its value.

The chart below shows where the stock has traded over the last year, with the 50-day and 200-day moving averages included.

Cytori Therapeutics, Inc., is a cell therapy company that develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. The firm was founded in 1996 and is headquartered in San Diego, California.

Be the first to comment

Leave a Reply

Your email address will not be published.


*